Healing & Repair
TB-500 (Thymosin Beta-4)
← Back to Library
Site-only / unverified FDA safety flag Site-only / unverified Repair Cellular Motility
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 5, 10, 15, 20 mg
Dosing window: Anytime
Receptor / target: G-Actin; TGF-beta
Properties: Not stated
Pre-mixed: No
Site-sourced protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 2.0mg to 2.5mg twice weekly | Loading Phase (Total of 4mg - 5mg per week). |
| Weeks 5-8 | 2.0mg once weekly | Maintenance Phase to hold systemic healing state. |
Site-provided protocol; not independently verified as label dosing unless graded otherwise on this page.
Alternative: Daily Micro-Dosing
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 500mcg - 750mcg daily | Keeps blood plasma levels perfectly stable, mitigating the 'head rush' some users feel from macro-dosing twice a week. |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Repair protocols depend on injury type, timing, loading, inflammation, and angiogenesis risk. Rodent or cell data can suggest a mechanism, but it does not prove a human dose or replace rehab and diagnosis. Entry context: target (G-Actin; TGF-beta); route Subcutaneous; timing Anytime. Site-only/low dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. TB-500 is commonly treated online as if every thymosin beta-4 paper applies to it. That is too loose: TB-500 is marketed as a fragment/related synthetic peptide, so protocol logic should stay conservative and avoid claiming full-protein thymosin beta-4 dosing proof.
Independent evidence
Independent safety notes: FDA lists TB-500 (thymosin beta-4 fragment LKKTETQ) among withdrawn nominated bulk substances with no identified human exposure data.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any site-sourced storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (site-sourced)
- Active cancer or high cancer risk: TB-500 promotes cell migration and angiogenesis via actin-mediated cellular motility and TGF-beta modulation; these mechanisms that accelerate healing in normal tissue also accelerate tumor cell migration, invasion, and neovascularization in malignant tissue. Site-only / unverified
- History of malignancy: the pro-migratory and pro-angiogenic mechanisms present theoretical risk of stimulating dormant or residual tumor cells; assess with care. Site-only / unverified
- Active cancer treatment (chemotherapy or radiation): TB-500's pro-migratory cell effects may theoretically interfere with cytotoxic therapy mechanisms by protecting cancer cells from treatment-induced damage. Site-only / unverified
- Pregnancy: no safety data; avoid. Site-only / unverified
- Breastfeeding: no safety data; avoid. Site-only / unverified
- Known hypersensitivity to Thymosin Beta-4, TB-500, or peptide excipients. Site-only / unverified
- Anticoagulant or antiplatelet therapy: potential additive effect via actin-mediated platelet function modulation; theoretical, but warrants monitoring. Site-only / unverified
- Proliferative vascular disorders: subjects with pathological neovascularization or arteriovenous malformations. Site-only / unverified
- Active autoimmune disorders: TB-500's immune modulatory properties (particularly TGF-beta modulation) carry theoretical risk of unpredictable immune activation in autoimmune-susceptible subjects. Site-only / unverified
- Pediatric use: no safety or efficacy data established. Site-only / unverified
Side effects (site-sourced)
- Lethargy and fatigue immediately following injection: the most commonly reported adverse effect; estimated 15-25% of users anecdotally; typically within 1-2 hours post-injection; resolves within the same day; related to the acute inflammatory modulation signal. Site-only / unverified
- Head rush or vasodilation sensation: warmth or blood rushing to the head within minutes of injection; reported in a minority of users; more common with macro-dose twice-weekly protocols than with daily micro-dosing; caused by angiogenic/vasodilatory mechanism; the daily micro-dosing protocol was specifically developed to mitigate this effect. Site-only / unverified
- Temporary dizziness: associated with the vasodilation response; transient. Site-only / unverified
- Injection site irritation: redness, minor swelling at subcutaneous injection site; estimated 20-30% of users anecdotally; normal tissue response. Site-only / unverified
- Headache: rare; less than 10% anecdotally; transient; likely vasodilation-mediated. Site-only / unverified
- Nausea: rare; less than 5% anecdotally; usually dose-related; less common than with BPC-157. Site-only / unverified
- Theoretical cancer cell migration risk: the most significant theoretical adverse effect; actin-mediated cell motility enhancement does not distinguish between healthy and malignant cells; this is the mechanistic basis for the cancer contraindication. Site-only / unverified
- Theoretical angiogenesis in pathological contexts: new vessel formation that supports wound healing in normal tissue could support tumor vascularization in oncological contexts. Site-only / unverified
- No significant hormonal side effects: unlike GH axis compounds, TB-500 does not affect the endocrine system, does not elevate cortisol or prolactin, and does not suppress natural hormonal production. Site-only / unverified
- No receptor desensitization: no documented downregulation of target pathways with standard cycle lengths; efficacy does not attenuate within a single cycle. Site-only / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: